AIM ImmunoTech Inks Deal With Thermo Fisher Scientific's PPD Clinical Research Business To Design AIM's Phase 3 Study In Use Of Ampligen Drug

AIM ImmunoTech Inc. Common Stock
Thermo Fisher Scientific Inc.

AIM ImmunoTech Inc. Common Stock

AIM

0.00

Thermo Fisher Scientific Inc.

TMO

0.00

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM's anticipated Phase 3 clinical trial in the use of the Company's drug Ampligen in the treatment of late-stage pancreatic cancer.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.